Imagion Biosystems Limited (ASX:IBX)
Australia
· Delayed Price · Currency is AUD 0.0130
-0.0010 (-7.14%)
Apr 24, 2025, 3:45 PM AEST
Imagion Biosystems Company Description
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance.
It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer.
It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent.
Imagion Biosystems Limited was incorporated in 2016 and is based in South Melbourne, Australia.
Imagion Biosystems Limited
| Country | Australia |
| Founded | 2016 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
Contact Details
Address: 96-100 Albert Road South Melbourne, 3205 Australia | |
| Phone | 61 3 9692 7222 |
| Website | imagionbiosystems.com |
Stock Details
| Ticker Symbol | IBX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | AUD |
| ISIN Number | AU000000IBX6 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Robert Romeo Proulx | Executive Chairman |
| Melanie Leydin C.A. | Non-Executive Director and Company Secretary |
| Ward Detwiler | Chief Business Officer |